Skip to content

Psilocybin-induced changes in electroencephalography link acute and long-term effects

Marek Nikolič, Tom Froese, Pedro A. M. Mediano, Vlastimil Koudelka, Jiřı́ Horáček, Filip Tylš, Tomáš Páleníček

Journal of Psychopharmacology September 4, 2026 DOI: 10.1177/02698811261473445 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial (crossover) Placebo-controlled Double-blind Peer reviewed
Sample size 20
Population Healthy participants (10 females)
Intervention Psilocybin
Dose ~0.26 mg/kg
Duration 24-hour sub-acute phase with 28-day follow-up
Measures Brief Psychiatric Rating Scale, Persisting Effects Questionnaire
Topics Psilocybin
Key findings Psilocybin acutely reduced alpha/beta power and increased gamma-band signal diversity, returning to baseline by 6 hours. Increased gamma diversity correlated with acute psychological effects (r = 0.71). At 24 hours, reduced delta/theta power correlated with positive life changes at 4 weeks (r = −0.47 to −0.57), independent of acute psychological intensity.

Abstract

Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized.

Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a medium dose ∼0.26 mg/kg of psilocybin. High-density resting-state electroencephalography and psychological states were assessed at baseline, 1, 3, 6, and 24 hours, with a 28-day follow-up.

Results: Psilocybin acutely decreased alpha/beta power and increased gamma-band signal diversity (1–3 hours; returning to baseline at 6 hours). Increased gamma diversity correlated with acute psychological effects (Brief Psychiatric Rating Scale, r = 0.71), with the largest increases observed in participants with lower baseline complexity. At 24 hours, reduced delta/theta power correlated with Positive Life Changes (Persisting Effects Questionnaire) at 4 weeks ( r = −0.47 to −0.57) but was independent of acute psychological intensity.

Conclusion: Our findings corroborate known acute effects while identifying a distinct sub-acute “afterglow” associated with long-term outcomes. The dissociation between acute psychology and 24-hour spectral shifts suggests that therapeutic benefits may be driven by sub-acute reductions in top-down cortical hierarchy. These results highlight the significance of the sub-acute window for psychological transformation and suggest normalized diversity as a viable baseline biomarker of individual responsiveness to psychedelic intervention.

Comparable studies

Other randomized controlled trials on psilocybin, most cited first.

Study Year Design Participants
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression 2021 Randomized controlled trial
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... 2020 Randomized controlled trial n = 24

Citations in the library

Explore topics